Home > Journals > International Angiology > Past Issues > International Angiology 2022 August;41(4) > International Angiology 2022 August;41(4):322-31



Publishing options
To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as


ORIGINAL ARTICLE  VENOUS DISEASE Editor’s choice • Free accessfree

International Angiology 2022 August;41(4):322-31

DOI: 10.23736/S0392-9590.22.04747-2


language: English

A prospective multicenter randomized clinical trial comparing endovenous laser ablation, using a 1470 nm diode laser in combination with a Tulip-TipTM fiber versus radiofrequency (Closure FAST™ VNUS®), in the treatment of primary varicose veins

Anne-Cathérine KEMPENEERS 1 , Beate BECHTER-HUGL 2, Sarah THOMIS 2, Daphne van den BUSSCHE 3, Marc E. VUYLSTEKE 3, Mathieu M. VUYLSTEKE 4

1 Department of General Surgery, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium; 2 Department of Vascular Surgery, University Hospitals of Leuven, Leuven, Belgium; 3 Department of Vascular Surgery, Sint-Andries Ziekenhuis, Tielt, Belgium; 4 Department of European Economics, College of Europe, Bruges, Belgium

BACKGROUND: The treatment of chronic venous disease, has largely shifted from high ligation and stripping to endovenous thermal ablation (EVTA) techniques, because of its comparable efficacy and lack of invasiveness. This clinical trial aimed to compare the efficacy of two thermal ablation techniques, endovenous laser ablation (EVLA) 1470-nm with Tulip-TipTM fiber and radiofrequency ablation (RFA) ClosureFastTM using a non-inferiority design for occlusion rate (primary outcome).
METHODS: A prospective multicenter randomized clinical trial randomized 280 patients for the treatment of great saphenous vein (GSV) reflux. Primary outcome was the GSV occlusion rate, secondary outcome factors were the possible side-effects of the treatment such as pain, ecchymosis, quality of Life (CIVIQ-20), revised Venous Clinical Severity Score (r-VCSS). One-year follow-up period.
RESULTS: The total occlusion rates at one year follow-up were 96.4% and 94.5% in the EVLA and RFA groups respectively (P=0.15). Regarding secondary outcomes, such as postoperative CIVIQ-20, r-VCSS, analgesia, absenteeism, there was no significant difference between both treatment groups.
CONCLUSIONS: RFA and EVLA, using a 1470 nm laser with Tulip-TipTM fiber, of the GSV results in equal occlusion rates at one year, with comparable postoperative pain and improved quality of life.

KEY WORDS: Laser ablation; Radiofrequency ablation; Varicose veins; Prospective studies; Pain, postoperative

top of page